Next Article in Journal
Guilt, Shame and Compassionate Imagery in War: Traumatized German Soldiers with PTSD, a Pilot Study
Next Article in Special Issue
The Dual Role of Neutrophils in Inflammatory Bowel Diseases
Previous Article in Journal
The Influence of Parental Emotional Neglect on Assault Victims Seeking Treatment for Depressed Mood and Alcohol Misuse: A Pilot Study
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2016, 5(10), 89; doi:10.3390/jcm5100089

Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD?

1
Institute of Inflammation and Ageing, University of Birmingham, Birmingham, B15 2TT, UK
2
Lung Function and Sleep, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TT, UK
3
Respiratory Research, Research and Development, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TT, UK
*
Author to whom correspondence should be addressed.
Academic Editors: Christophe Dubois and Laurence Panicot-Dubois
Received: 24 August 2016 / Revised: 17 September 2016 / Accepted: 20 September 2016 / Published: 11 October 2016
(This article belongs to the Special Issue Neutrophil Functions: From Immunity to Disease)
View Full-Text   |   Download PDF [1234 KB, uploaded 11 October 2016]   |  

Abstract

Drug classes used in the treatment of Chronic Obstructive Pulmonary Disease (COPD) have not changed for many years, and none to date have shown disease-modifying activity. Statins are used to help reduce cardiovascular risk, which is high in many patients with COPD. Their use has been associated with improvements in some respiratory manifestations of disease and reduction in all-cause mortality, with greatest reductions seen in patients with the highest inflammatory burden. The mechanism for these effects is poorly understood. Neutrophils are key effector cells in COPD, and correlate with disease severity and inflammation. Recent in vitro studies have shown neutrophil functions are dysregulated in COPD and this is thought to contribute both to the destruction of lung parenchyma and to the poor responses seen in infective exacerbations. In this article, we will discuss the potential utility of statins in COPD, with a particular emphasis on their immune-modulatory effects as well as presenting new data regarding the effects of statins on neutrophil function in vitro. View Full-Text
Keywords: neutrophil; inflammation; COPD; statins; chemotaxis; simvastatin neutrophil; inflammation; COPD; statins; chemotaxis; simvastatin
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Walton, G.M.; Stockley, J.A.; Griffiths, D.; Sadhra, C.S.; Purvis, T.; Sapey, E. Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD? J. Clin. Med. 2016, 5, 89.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top